Establishment Labs Holdings, Inc. ESTA

For growth investors, Establishment Labs Holdings (NASDAQ:ESTA) presents a compelling equity thesis: a medical aesthetics disruptor transitioning from cash-burning expansion to sustainable, profitable scale. Evaluating the company’s long-term fundamentals, such as its trajectory of multi-year revenue growth, operating cash flow generation, return on invested capital/ROIC, and ultimate free cash flow conversion, reveals a business at […]

NEW YORK, September 21, 2026--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced the presentation of new clinical and scientific data supporting Breast Tissue Preservation and its Minimally Invasive Platform. Establishment Labs also announced the product line extensions of both Mia® and Preservé™ with new sizes and supporting tools. The announcement

Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.

Equity Insider News Commentary - The global medical aesthetics market has quietly become one of the most durable growth stories in healthcare. Multiple market-research firms size it at roughly US$22 billion to US$23 billion in 2026, with projections reaching approximately US$40 billion by 2031 at a compound annual growth rate near 12 percent, and other forecasts running higher still over longer horizons. The drivers are structural: an aging population, rising disposable incomes, the normalizatio

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Discovery Fund”. A copy of the letter is available to download here. Baron Discovery Fund appreciated by 19.08% (Institutional Shares) in the quarter, underperforming the Russell 2000 Growth Index, which gained 25.71%. This lag was primarily due to a momentum-driven “AI […]

Establishment Labs Holdings has delivered a strong 122.5% return over the last year, yet current checks suggest the stock no longer looks obviously cheap, with the Discounted Cash Flow (DCF) intrinsic value estimate sitting close to the market price while market multiples lean expensive. Establishment Labs Holdings is up 122.5% over the past year, which puts extra focus on whether recent gains already reflect the company’s growth prospects. Recent company updates around global execution and...

Company raises full-year revenue guidance to $269-$271 million as minimally invasive platform gains traction and U.S. market expansion accelerates.

Establishment Labs (ESTA) delivered earnings and revenue surprises of -14.71% and +3.53%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

NEW YORK, August 06, 2026--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2026.

NEW YORK, July 23, 2026--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2026, before the market opens on Thursday, August 6, 2026, and will host a conference call at 8:30 AM ET that day to discuss those results.

NEW YORK, June 29, 2026--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Taylor Harris to its Board of Directors.

NEW YORK, June 25, 2026--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, will be added as a member of the US small-cap Russell 2000® Index, effective when the US market opens on June 29th as part of the 2026 Russell indexes reconstitution.

Raj Denhoy Headshot Raj Denhoy, Chief Financial Officer, Route 92 Medical WEST JORDAN, Utah, May 18, 2026 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the appointment of Raj Denhoy to the role of Chief Financial Officer (CFO) effective today. “Route 92 Medical has built a strong position in neurovascular intervention,” said Raj Denhoy, CFO at Route 92 Med

This U.S.-based coal producer operates integrated mining and export facilities, supplying power generators and industrial clients worldwide.

Appian provides low-code automation tools for enterprise clients, enabling rapid digital transformation across multiple industries.